Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine plus Bevacizumab in Advanced Pancreatic Cancer
NCT00088894Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2004
- Primary completion
- Jun 2006
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pancreatic cancer (PC) comparing Gemcitabine + Bevacizumab with Gemcitabine + Placebo (2 arms). Primary endpoints: Overall Survival at 7 years, Discrepancies in the response rate between the two genotypic groups at 7 years and 1 more. Started Jun 2004; status: completed.
02
Drugs
bevacizumab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00088894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00088894.